Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported outcomes (PROs).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: S.A. Hurvitz, R.G.W. Quek, N.C. Turner, M.L. Telli, H.S. Rugo, A. Mailliez, J. Ettl, E. Grischke, L.A. Mina, J. Balma ña, P.A. Fasching, H. Bhattacharyya, A.L. Hannah, M.E. Robson, A.M. Wardley Tags: Original Research Source Type: research